Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Booking Holdings Inc (BKNG) vs Merck & Co., Inc. (MRK) Price & Performance

Booking Holdings IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Booking Holdings Inc vs Merck & Co., Inc. — how do they compare? Booking Holdings Inc trades at $212.62 (market cap $159.95B), while Merck & Co., Inc. trades at $133.94 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 2× Booking Holdings Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

BKNGMRK
Market Cap
$159.95B$321.77B
Sector
Consumer CyclicalHealth
52-Week High
$228.83$131.84
52-Week Low
$154.13$77.60
Enterprise Value
$163.43B$368.53B
Dividend Yield
0.79%2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Booking Holdings Inc

Booking Holdings (BKNG) trades at $211.73, down 0.54% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates at $2.54 versus $2.43 expected, driven by resilient travel demand. Revenue grew to $26.92B in 2025, with a net income margin of 25.53%, while cash flow from operations remains robust at $9.41B. Analyst consensus is strongly bullish with a $239.31 price target.

Outlook is positive given earnings beats and travel recovery, but risks include geopolitical volatility and high valuation multiples. The stock offers growth potential with a wide moat in online travel, though debt levels and competitive pressures warrant monitoring. Institutional sentiment supports upside, with 64% of analysts rating it Buy.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Booking Holdings Inc

Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.

Read more on BKNG

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK